«« | Feb 2008 | »» | ||||
S | M | T | W | T | F | S |
1
|
2
|
|||||
3 | 4 | 5 | 6 | 7 | 8 | 9 |
10 | 11 | 12 | 13 | 14 | 15 | 16 |
17 | 18 | 19 | 20 | 21 | 22 | 23 |
24 | 25 | 26 | 27 | 28 | 29 |
FoxNews:
Displaced disaster survivors at greatest mental illness/substance abuse risk
Reuters:
Work stress linked to coronary heart disease
WFSB-TV:
Psychotherapy has rapid positive effect on OCD patients' brain activity
Italian pharmaceutical company Abiogen Pharma has begun a phase II clinical trial evaluating its anti anxiety drug ABIO 08/01.
Being developed to treat clinical anxiety disorders such as Panic Disorder and Generalized Anxiety Disorder, ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives.
In phase I studies ABIO 08-01 demonstrated a good profile of safety and tolerability. Moreover, EEG/ERP mapping has provided evidence about peculiar CNS effects of ABIO 08/01. "Comparisons of imaging with previous data arisen from studies conducted at the same investigational centre, present a pharmacological profile of ABIO 08/01 which seems to be extremely innovative," said the company.
tags: panic disorder drug trial generalized anxiety disorder
links: digg this del.icio.us technorati reddit